Markus Niggli

1.7k total citations · 1 hit paper
25 papers, 1.2k citations indexed

About

Markus Niggli is a scholar working on Hematology, Genetics and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Markus Niggli has authored 25 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Hematology, 10 papers in Genetics and 4 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Markus Niggli's work include Hemophilia Treatment and Research (19 papers), Platelet Disorders and Treatments (9 papers) and Blood Coagulation and Thrombosis Mechanisms (6 papers). Markus Niggli is often cited by papers focused on Hemophilia Treatment and Research (19 papers), Platelet Disorders and Treatments (9 papers) and Blood Coagulation and Thrombosis Mechanisms (6 papers). Markus Niggli collaborates with scholars based in Switzerland, United States and Germany. Markus Niggli's co-authors include Ido Paz‐Priel, Christophe Schmitt, Johannes Oldenburg, Víctor Jiménez‐Yuste, Gallia G. Levy, Johnny Mahlangu, Michael U. Callaghan, Maria Elisa Mancuso, Midori Shima and Elina Asikanius and has published in prestigious journals such as New England Journal of Medicine, Blood and Clinical Pharmacokinetics.

In The Last Decade

Markus Niggli

24 papers receiving 1.1k citations

Hit Papers

Emicizumab Prophylaxis in Patients Who Have Hemophilia A ... 2018 2026 2020 2023 2018 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors
    2018 503 citations Johnny Mahlangu, Johannes Oldenburg et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Markus Niggli Switzerland 13 887 254 190 162 103 25 1.2k
Jonathan M. Flanagan United States 10 227 0.3× 238 0.9× 17 0.1× 80 0.5× 13 0.1× 18 403
Athanasios Fountas Greece 12 35 0.0× 56 0.2× 220 1.2× 116 0.7× 129 1.3× 26 492
Takehiko Sambe Japan 6 186 0.2× 66 0.3× 21 0.1× 62 0.4× 49 0.5× 29 347
Ali Awsat Mellati Iran 10 61 0.1× 111 0.4× 25 0.1× 111 0.7× 13 0.1× 28 370
Richard E. Valocik United States 11 127 0.1× 43 0.2× 15 0.1× 55 0.3× 48 0.5× 18 365
Tomoko Saito Japan 8 33 0.0× 30 0.1× 121 0.6× 136 0.8× 28 0.3× 12 410
M F Gonzales France 6 25 0.0× 54 0.2× 259 1.4× 109 0.7× 48 0.5× 6 536
Hannah C. Timmins Australia 15 118 0.1× 73 0.3× 9 0.0× 54 0.3× 32 0.3× 37 540
Tiffany Li Australia 15 129 0.1× 58 0.2× 8 0.0× 40 0.2× 38 0.4× 38 545
Liviu Niculescu United States 9 241 0.3× 34 0.1× 3 0.0× 238 1.5× 28 0.3× 29 515

Countries citing papers authored by Markus Niggli

Since Specialization
Citations

This map shows the geographic impact of Markus Niggli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus Niggli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus Niggli more than expected).

Fields of papers citing papers by Markus Niggli

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Markus Niggli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus Niggli. The network helps show where Markus Niggli may publish in the future.

Co-authorship network of co-authors of Markus Niggli

This figure shows the co-authorship network connecting the top 25 collaborators of Markus Niggli. A scholar is included among the top collaborators of Markus Niggli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Markus Niggli. Markus Niggli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mahlangu, Johnny, Víctor Jiménez‐Yuste, Markus Niggli, et al.. (2024). Long-term outcomes with emicizumab in hemophilia A without inhibitors: results from the HAVEN 3 and 4 studies. Research and Practice in Thrombosis and Haemostasis. 8(2). 102364–102364. 8 indexed citations
2.
Kiialainen, Anna, Joanne I. Adamkewicz, Claire Petry, et al.. (2023). Pharmacokinetics and coagulation biomarkers in children and adults with hemophilia A receiving emicizumab prophylaxis every 1, 2, or 4 weeks. Research and Practice in Thrombosis and Haemostasis. 8(1). 102306–102306. 4 indexed citations
3.
Pipe, Steven W., Peter W. Collins, Christophe Dhalluin, et al.. (2023). Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial. Blood. 143(14). 1355–1364. 31 indexed citations
4.
Pipe, Steven W., Peter W. Collins, Christophe Dhalluin, et al.. (2023). Emicizumab Prophylaxis in Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 7 Study. Blood. 142(Supplement 1). 505–505. 4 indexed citations
5.
Kiialainen, Anna, Markus Niggli, Christine L. Kempton, et al.. (2022). Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study. Haemophilia. 28(6). 1033–1043. 23 indexed citations
6.
Kruse‐Jarres, Rebecca, Flora Peyvandi, Johannes Oldenburg, et al.. (2022). Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies. Blood Advances. 6(24). 6140–6150. 30 indexed citations
7.
Skinner, Mark W., Claude Négrier, Ido Paz‐Priel, et al.. (2021). The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies. Haemophilia. 27(5). 854–865. 34 indexed citations
8.
Schmitt, Christophe, Thomas Emrich, Sammy Chebon, et al.. (2021). Low immunogenicity of emicizumab in persons with haemophilia A. Haemophilia. 27(6). 984–992. 46 indexed citations
9.
10.
Callaghan, Michael U., Claude Négrier, Ido Paz‐Priel, et al.. (2020). Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood. 137(16). 2231–2242. 170 indexed citations
11.
Callaghan, Michael U., Claude Négrier, Ido Paz‐Priel, et al.. (2020). Safety and Efficacy of Emicizumab in Persons with Hemophilia a with or without FVIII Inhibitors: Pooled Data from Four Phase III Studies (HAVEN 1-4). Blood. 136(Supplement 1). 3–5. 4 indexed citations
12.
Umbricht, Daniel, Markus Niggli, Patricia Sanwald Ducray, et al.. (2020). Randomized, Double-Blind, Placebo-Controlled Trial of the mGlu2/3 Negative Allosteric Modulator Decoglurant in Partially Refractory Major Depressive Disorder. The Journal of Clinical Psychiatry. 81(4). 31 indexed citations
13.
14.
Callaghan, Michael U., Benjamin Trzaskoma, Richard H. Ko, et al.. (2019). Factor VIII Use in the Treatment of Breakthrough Bleeds in Hemophilia A Patients without Inhibitors on Emicizumab Prophylaxis: The Phase 3 HAVEN 3 Study Experience. Blood. 134(Supplement_1). 2395–2395. 5 indexed citations
15.
Révil, Cédric, Markus Niggli, Sammy Chebon, et al.. (2019). Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial. Current Medical Research and Opinion. 35(12). 2079–2087. 21 indexed citations
16.
Bogman, Katrijn, Jochen Brumm, Carsten Hofmann, et al.. (2019). Assessment of Drug–Drug Interactions between Taspoglutide, a Glucagon-Like Peptide-1 Agonist, and Drugs Commonly Used in Type 2 Diabetes Mellitus: Results of Five Phase I Trials. Clinical Pharmacokinetics. 58(9). 1205–1214. 2 indexed citations
17.
Jiménez‐Yuste, Víctor, Midori Shima, Ido Paz‐Priel, et al.. (2018). Preference for Emicizumab over Prior Factor Treatments: Results from the HAVEN 3 and HAVEN 4 Studies. Blood. 132(Supplement 1). 1187–1187. 5 indexed citations
18.
Lambert, Nathalie, et al.. (2016). Effect of varying degrees of renal impairment on the pharmacokinetics and tolerability of taspoglutide. Diabetes Obesity and Metabolism. 19(4). 537–544. 4 indexed citations
19.
Rosenstock, Julio, et al.. (2009). Long‐term 2‐year safety and efficacy of vildagliptin compared with rosiglitazone in drug‐naïve patients with type 2 diabetes mellitus. Diabetes Obesity and Metabolism. 11(6). 571–578. 49 indexed citations
20.
Pan, Changyu, Wenying Yang, Jacqueline Barona, et al.. (2008). Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24‐week, double‐blind, randomized trial. Diabetic Medicine. 25(4). 435–441. 144 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jonathan M. Flanagan Breakdown of academic impact, for papers by Athanasios Fountas Breakdown of academic impact, for papers by Takehiko Sambe Breakdown of academic impact, for papers by Ali Awsat Mellati Breakdown of academic impact, for papers by Richard E. Valocik Breakdown of academic impact, for papers by Tomoko Saito Breakdown of academic impact, for papers by M F Gonzales Breakdown of academic impact, for papers by Hannah C. Timmins Breakdown of academic impact, for papers by Tiffany Li Breakdown of academic impact, for papers by Liviu Niculescu
Rankless by CCL
2026